Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Cancer Chemother Pharmacol

Search In Journal Title:

Abbravation: Cancer Chemotherapy and Pharmacology

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1001/jama.296.19.2315-a

Search In DOI:

ISSN

1432-0843

Search In ISSN:
Search In Title Of Papers:

Successful treatment with a rituximabbased regime

Authors: Pasquale Niscola Roberto Palumbo Laura Scaramucci Andrea Tendas Luca Cupelli Marco Giovannini Daniela Piccioni Teresa Dentamaro Alessio Pio Perrotti Paolo de Fabritiis
Publish Date: 2008/05/24
Volume: 63, Issue: 4, Pages: 759-
PDF Link

Abstract

The treatment approach to non Hodgkin lymphoma NHL in patients with renal failure is a challenging concern The case of a dialysed patient suffering from a splenic marginal zone lymphoma SMZL with villous lymphocytes who received rituximab associated with chlorambucil as firstline treatment is here describedA 70yearold woman was admitted to the hospital in July 2007 because of massive splenomegaly lymphocytosis moderate anaemia and severe thrombocytopenia A comprehensive work up including a body CT scan was performed Extensive spleen enlargement and deep abdominal adenomegalies but not enlarged nodes suitable for an excision biopsy were found According to morphological features and immunophenotype CD19 CD79a CD22 CD20 CD45 CD79b CD52 FMC7 and lambda positive Bcells a diagnosis of SMZL was made The past medical history was notably remarkable Indeed she was affected by longlasting hypertension and diabetes mellitus complicated by chronic

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
  2. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
  3. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab
  4. Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages
  5. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
  6. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
  7. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer
  8. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
  9. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy- d -glucose in tumor cells treated under hypoxic vs aerobic conditions
  10. Anticancer effect of ( E )-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization
  11. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil
  12. A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
  13. Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients
  14. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
  15. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
  16. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model
  17. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib
  18. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
  19. Hypericin—an inhibitor of proteasome function
  20. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis
  21. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
  22. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
  23. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
  24. HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells
  25. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
  26. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma
  27. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin
  28. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
  29. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
  30. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients
  31. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
  32. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer
  33. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
  34. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
  35. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
  36. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
  37. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer
  38. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
  39. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells
  40. Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats
  41. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
  42. The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines
  43. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
  44. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
  45. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
  46. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
  47. The relative bioavailability of gefitinib administered by granular formulation
  48. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors
  49. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy
  50. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling
  51. Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy
  52. Phase II study of rubitecan in recurrent or metastatic head and neck cancer
  53. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer
  54. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
  55. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
  56. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
  57. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma
  58. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
  59. Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line
  60. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer
  61. Defining clinically relevant molecular subsets of lung cancer
  62. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
  63. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
  64. A late phase II study of S-1 for metastatic pancreatic cancer
Search Result: